Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts UCB will utilize Aetion's analytics platform to align with U.S. payers on treatment outcomes and value PR Newswire NEW YORK, Oct. 7, 2020 NEW YORK , ...
UCB Achieves Important Regulatory Milestone for Bimekizumab - The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis ...
Quick Take Inhibikase Therapeutics ( IKT ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases. IKT is still at a ...
ATLANTA , Aug. 31, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of the Phase 3 study results of VIMPAT ® (lacosamide) CV as adjunctive treatment for uncontrolled primary generalized tonic-clonic seizures (PGTCS), in the ...
- UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further potentia...
UCB SA (UCBJF) Q2 2020 Earnings Conference Call July 27, 2020 8:00 AM ET Company Participants Antje Witte - Vice President Investor Relations Jean-Christophe Tellier - Chief Executive Officer and Executive Director Iris Löw-Friedrich - Chief Medical Officer Emmanuel Caeyma...
The following slide deck was published by UCB SA in conjunction with their 2020 Q2 earnings Read more ...
- UCB's resilient product portfolio drives continued company growth BRUSSELS , July 27, 2020 /PRNewswire/ -- Revenue increased to € 2.6 billion and net sales to € 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively Unde...
ATLANTA and PARSIPPANY, N.J. , July 7, 2020 /PRNewswire/ -- UCB and Ferring Pharmaceuticals Inc. today announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA ® (certolizumab pegol) in the United State...
BRUSSELS , June 12, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the Americ...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...